RecruitingSample study (AI-generated)UK-VCSR-2026-00001
Novel immunotherapy for canine lymphoma
This is an example listing generated for demonstration purposes. It is not a real recruiting study.
Interventional · Oncology · Investigator: Dr Sarah Mitchell
Canine
Study overview
This prospective multi-centre study evaluates a novel monoclonal antibody immunotherapy for dogs with newly diagnosed B-cell lymphoma. The trial aims to improve remission rates and quality of life compared with standard chemotherapy protocols. Participating centres across England and Scotland will enrol eligible dogs following confirmation of diagnosis by cytology or histopathology. Owners receive full disclosure of risks, benefits, and alternative treatment options before consent.
Condition
Lymphoma
Eligibility criteria
Inclusion
Dogs over 1 year with confirmed B-cell lymphoma.
Locations
England, Scotland
Sponsor / institution
University of Edinburgh
Ethical and regulatory approvals
AWERB approval REF-2026-001
Statement of ethical considerations
Independent ethical review completed.
Last updated 16 August 2026 · Published 15 January 2026